Pharma Focus Asia
KP - Sustainable Packaging Solutions

Novo Nordisk Invests US$2.32billion (DKK 17 bn) in Manufacturing Facility Expansion

Introduction:

Novo Nordisk univels plans for the construction and expansion of its current facility. The expansion of the existing manufacturing facility will be located in Kalundborg, Denmark.

Features:

The project includes construction of three new manufacturing facilities and expansion of one existing facility.

The state-of-the-art productionfacility will be automated with advanced technologies.

The new construction featured with additional capacitywill support the vast global value chain in manufacturing of active pharmaceutical ingredients (API) to assembly and packaging.

The expansion benefits the additional capacity  for the production of existing and  future oral and injectable products.In addition, this investment will increase the manufacturing setup.

The project is expected to be completed by 2027. The new production facility is anticipated tocreate around 400 new jobs and more than 2,500 external jobs during the construction phase.

Specifications:

NameNovo Nordisk
TypeExpansion & Construction
BudgetUS$2.32 billion (DKK 17 bn)
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024Equinix accelerated medical research...CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?